Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Hedditch, EL, Gao, B, Russell, AJ, Lu, Y, Emmanuel, C, Beesley, J, Johnatty, SE, Chen, X, Harnett, P, George, J, Australian Ovarian Cancer Study Group, , Williams, RT, Flemming, C, Lambrechts, D, Despierre, E, Lambrechts, S, Vergote, I, Karlan, B, Lester, J, Orsulic, S, Walsh, C, Fasching, P, Beckmann, MW, Ekici, AB, Hein, A, Matsuo, K, Hosono, S, Nakanishi, T, Yatabe, Y, Pejovic, T, Bean, Y, Heitz, F, Harter, P, du Bois, A, Schwaab, I, Hogdall, E, Kjaer, SK, Jensen, A, Hogdall, C, and Lundvall, L et al. "ABCA transporter gene expression and poor outcome in epithelial ovarian cancer." Journal of the National Cancer Institute 106, no. 7 (July 2014).

Full Text

Block, MS, Charbonneau, B, Vierkant, RA, Fogarty, Z, Bamlet, WR, Pharoah, PDP, Georgia Chenevix-Trench, , for AOCS, , /ACS Group, , Rossing, MA, Cramer, D, Pearce, CL, Schildkraut, J, Menon, U, Kjaer, SK, Levine, DA, Gronwald, J, Culver, HA, Whittemore, AS, Karlan, BY, Lambrechts, D, Wentzensen, N, Kupryjanczyk, J, Chang-Claude, J, Bandera, EV, Hogdall, E, Heitz, F, Kaye, SB, Fasching, PA, Campbell, I, Goodman, MT, Pejovic, T, Bean, YT, Hays, LE, Lurie, G, Eccles, D, Hein, A, and Beckmann, MW et al. "Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 23, no. 7 (July 2014): 1421-1427.

Full Text

Havrilesky, LJ, Secord, AA, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, S, Celia, D, Weinfurt, K, Abernethy, AP, and Reed, SD. "Relative influence of factors determining a woman's preference for treatment options in ovarian cancer." May 20, 2014.

Scholars@Duke

Earp, MA, Kelemen, LE, Magliocco, AM, Swenerton, KD, Chenevix-Trench, G, Australian Cancer Study, , Australian Ovarian Cancer Study Group, , Lu, Y, Hein, A, Ekici, AB, Beckmann, MW, Fasching, PA, Lambrechts, D, Despierre, E, Vergote, I, Lambrechts, S, Doherty, JA, Rossing, MA, Chang-Claude, J, Rudolph, A, Friel, G, Moysich, KB, Odunsi, K, Sucheston-Campbell, L, Lurie, G, Goodman, MT, Carney, ME, Thompson, PJ, Runnebaum, IB, Dürst, M, Hillemanns, P, Dörk, T, Antonenkova, N, and Bogdanova, N et al. "Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA." Hum Genet 133, no. 5 (May 2014): 481-497.

Full Text

Witkowski, L, Carrot-Zhang, J, Albrecht, S, Fahiminiya, S, Hamel, N, Tomiak, E, Grynspan, D, Saloustros, E, Nadaf, J, Rivera, B, Gilpin, C, Castellsagué, E, Silva-Smith, R, Plourde, F, Wu, M, Saskin, A, Arseneault, M, Karabakhtsian, RG, Reilly, EA, Ueland, FR, Margiolaki, A, Pavlakis, K, Castellino, SM, Lamovec, J, Mackay, HJ, Roth, LM, Ulbright, TM, Bender, TA, Georgoulias, V, Longy, M, Berchuck, A, Tischkowitz, M, Nagel, I, Siebert, R, Stewart, CJR, Arseneau, J, McCluggage, WG, and Clarke, BA et al. "Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type." Nature genetics 46, no. 5 (May 2014): 438-443.

Full Text

Zhang, C, Havrilesky, LJ, Broadwater, G, Di Santo, N, Ehrisman, JA, Lee, PS, Berchuck, A, Alvarez Secord, A, Bean, S, Bentley, RC, and Valea, FA. "Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: A single institution study of 458 patients." Gynecologic Oncology 133, no. 2 (May 2014): 211-215.

Full Text

Zhang, C, Havrilesky, LJ, Broadwater, G, Di Santo, N, Ehrisman, JA, Lee, PS, Berchuck, A, Alvarez Secord, A, Bean, S, Bentley, RC, and Valea, FA. "Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients." Gynecologic oncology 133, no. 2 (May 2014): 211-215.

Full Text

Havrilesky, L, Secord, A, Ehrisman, J, Berchuck, A, Valea, F, Lee, P, Cella, D, Weinfurt, K, Abernethy, A, and Reed, S. "Relative Influence of Factors Determining a Woman’s Preference for Treatment Options in Ovarian Cancer: A Discrete Choice Experiment." May 2014.

Full Text

Charbonneau, B, Moysich, KB, Kalli, KR, Oberg, AL, Vierkant, RA, Fogarty, ZC, Block, MS, Maurer, MJ, Goergen, KM, Fridley, BL, Cunningham, JM, Rider, DN, Preston, C, Hartmann, LC, Lawrenson, K, Wang, C, Tyrer, J, Song, H, deFazio, A, Johnatty, SE, Doherty, JA, Phelan, CM, Sellers, TA, Ramirez, SM, Vitonis, AF, Terry, KL, Van Den Berg, D, Pike, MC, Wu, AH, Berchuck, A, Gentry-Maharaj, A, Ramus, SJ, Diergaarde, B, Shen, H, Jensen, A, Menkiszak, J, Cybulski, C, Lubiłski, J, and Ziogas, A et al. "Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome." Cancer immunology research 2, no. 4 (April 2014): 332-340.

Full Text

Witkowski, L, Carrot-Zhang, J, Albrecht, S, Fahiminiya, S, Hamel, N, Tomiak, E, Grynspan, D, Saloustros, E, Nadaf, J, Rivera, B, Gilpin, C, Castellsagué, E, Silva-Smith, R, Plourde, F, Wu, M, Saskin, A, Arseneault, M, Karabakhtsian, RG, Reilly, EA, Ueland, FR, Margiolaki, A, Pavlakis, K, Castellino, SM, Lamovec, J, Mackay, HJ, Roth, LM, Ulbright, TM, Bender, TA, Georgoulias, V, Longy, M, Berchuck, A, Tischkowitz, M, Nagel, I, Siebert, R, Stewart, CJR, Arseneau, J, McCluggage, WG, and Clarke, BA et al. "Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type." Nature Genetics 46, no. 5 (March 23, 2014): 438-443.

Full Text

Pages